Ewa Ninio
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ewa Ninio has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Dominique Stengel
3 shared publicationsChristoph Bickel
2 shared publicationsFrançois Cambien
2 shared publicationsHans J. Rupprecht
2 shared publicationsLaurence Tiret
2 shared publicationsStefan Blankenberg
2 shared publications
Latest Publications
- 20 June 2017
- Published by Springer Nature
- p. 2505-2509
Lipid Mediators
- 26 November 2015
- Published by Springer Nature
- p. 1-4
Lipid Mediators
- 1 March 2005
- Published by Wolters Kluwer Health in Current Opinion in Clinical Nutrition and Metabolic Care
- Vol. 8 (2) , 123-131
Phospholipid mediators in the vessel wall: involvement in atherosclerosis
This review provides a brief update on the involvement of major phospholipid mediators, with the emphasis on platelet-activating factor and its analogues generated upon the oxidation of lipoproteins in vascular pathology, including atherogenesis. Phospholipid mediators are produced during inflammation by various enzymes, mostly from pre-existing membrane phospholipids, and trigger cellular signaling via G-coupled receptors. A short description of lysophosphatidic acid, lysophosphocholine and sphingosine-1 phosphate receptors and their actions is given, but attention is focused mainly on platelet-activating factor and its analogues. The majority of these mediators participate in leukocyte adhesiveness to the endothelium, leukocyte transmigration into the vessel wall and the subsequent formation of various chemokines leading to foam cell formation and smooth muscle cell proliferation and dedifferentiation. Platelet-activating factor and platelet-activating factor-like phospholipids are degraded in plasma by the lipoprotein-bound enzyme of myeloid origin, PAF-acetylhydrolase, also known as LDL-PLA2. Although the overexpression of PAF-acetylhydrolase shows marked anti-atherogenic properties in animal models, epidemiological data in the Caucasian population have demonstrated that its level might be a risk factor for cardiovascular disease. Recent genetic studies have shown, however, that the A379V polymorphism of this gene, responsible for slightly higher enzymatic activity, exerts a protective effect, probably by modifying the enzyme function towards a less atherogenic form. Phospholipid-borne mediators are certainly key players in inflammation and thus in atherosclerosis. The generation of such biologically active molecules is possibly dependent on nutritional habits and the availability of antioxidants, including enzymes protective against oxidative damage, including PAF-acetylhydrolase.
- 1 March 2005
- Published by Wolters Kluwer Health in Current Opinion in Clinical Nutrition and Metabolic Care
- Vol. 8 (2) , 123-131
Phospholipid mediators in the vessel wall: involvement in atherosclerosis
This review provides a brief update on the involvement of major phospholipid mediators, with the emphasis on platelet-activating factor and its analogues generated upon the oxidation of lipoproteins in vascular pathology, including atherogenesis. Phospholipid mediators are produced during inflammation by various enzymes, mostly from pre-existing membrane phospholipids, and trigger cellular signaling via G-coupled receptors. A short description of lysophosphatidic acid, lysophosphocholine and sphingosine-1 phosphate receptors and their actions is given, but attention is focused mainly on platelet-activating factor and its analogues. The majority of these mediators participate in leukocyte adhesiveness to the endothelium, leukocyte transmigration into the vessel wall and the subsequent formation of various chemokines leading to foam cell formation and smooth muscle cell proliferation and dedifferentiation. Platelet-activating factor and platelet-activating factor-like phospholipids are degraded in plasma by the lipoprotein-bound enzyme of myeloid origin, PAF-acetylhydrolase, also known as LDL-PLA2. Although the overexpression of PAF-acetylhydrolase shows marked anti-atherogenic properties in animal models, epidemiological data in the Caucasian population have demonstrated that its level might be a risk factor for cardiovascular disease. Recent genetic studies have shown, however, that the A379V polymorphism of this gene, responsible for slightly higher enzymatic activity, exerts a protective effect, probably by modifying the enzyme function towards a less atherogenic form. Phospholipid-borne mediators are certainly key players in inflammation and thus in atherosclerosis. The generation of such biologically active molecules is possibly dependent on nutritional habits and the availability of antioxidants, including enzymes protective against oxidative damage, including PAF-acetylhydrolase.
- Open Access
- 28 April 2004
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 13 (13) , 1341-1351
Platelet-activating factor-acetylhydrolase and PAF-receptor gene haplotypes in relation to future cardiovascular event in patients with coronary artery disease
Oxidation of low density lipoproteins is an initial step of atherogenesis that generates pro-inflammatory phospholipids, including platelet-activating factor (PAF) and its analogs. PAF is degraded by PAF-acetylhydrolase (PAF-AH), a circulating enzyme having both pro- and anti-inflammatory activities. PAF-AH activity has been postulated to be a risk factor for coronary artery disease (CAD); however, whether PAF-AH has a causal role or is simply a marker of risk is unclear. The aim of this study was to relate the variability of the genes encoding PAF-AH (PLA2G7) and the PAF-receptor (PTAFR) to the risk of CAD and its complications. All polymorphisms located in putatively functional regions were investigated in a prospective cohort of CAD patients (n=1314) and a group of healthy controls (n=485). The whole gene variability was investigated in relation to case–control status, prospective cardiovascular outcome and plasma PAF-AH levels by means of haplotype analyses. All analyses indicated an effect of the PLA2G7/A379V polymorphism independent of the other polymorphisms. The V379 allele was less frequent in CAD patients than in controls and was associated with a lower risk of future cardiovascular events, suggesting that this allele might be protective against the development of CAD. The V379 allele was also associated with a weak increase of plasma PAF-AH activity that was unlikely to explain the protective effect of the allele on risk. A more likely interpretation is that the A379V polymorphism might modify the enzyme function towards a more anti-atherogenic form. Polymorphisms of the PTAFR gene were not related to any phenotype.
- 28 April 2004
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 13 (13) , 1341-1351
Open AccessPlatelet-activating factor-acetylhydrolase and PAF-receptor gene haplotypes in relation to future cardiovascular event in patients with coronary artery disease
Oxidation of low density lipoproteins is an initial step of atherogenesis that generates pro-inflammatory phospholipids, including platelet-activating factor (PAF) and its analogs. PAF is degraded by PAF-acetylhydrolase (PAF-AH), a circulating enzyme having both pro- and anti-inflammatory activities. PAF-AH activity has been postulated to be a risk factor for coronary artery disease (CAD); however, whether PAF-AH has a causal role or is simply a marker of risk is unclear. The aim of this study was to relate the variability of the genes encoding PAF-AH (PLA2G7) and the PAF-receptor (PTAFR) to the risk of CAD and its complications. All polymorphisms located in putatively functional regions were investigated in a prospective cohort of CAD patients (n=1314) and a group of healthy controls (n=485). The whole gene variability was investigated in relation to case–control status, prospective cardiovascular outcome and plasma PAF-AH levels by means of haplotype analyses. All analyses indicated an effect of the PLA2G7/A379V polymorphism independent of the other polymorphisms. The V379 allele was less frequent in CAD patients than in controls and was associated with a lower risk of future cardiovascular events, suggesting that this allele might be protective against the development of CAD. The V379 allele was also associated with a weak increase of plasma PAF-AH activity that was unlikely to explain the protective effect of the allele on risk. A more likely interpretation is that the A379V polymorphism might modify the enzyme function towards a more anti-atherogenic form. Polymorphisms of the PTAFR gene were not related to any phenotype.
- Open Access
- 1 July 2003
- Published by Elsevier in Journal of Lipid Research
- Vol. 44 (7) , 1381-1386
Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis
- 1 July 2003
- Published by Elsevier in Journal of Lipid Research
- Vol. 44 (7) , 1381-1386
Open AccessPlasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis
- Open Access
- 15 August 2001
- Published by Wiley in European Journal of Biochemistry
- Vol. 268 (16) , 4489-4496
Oxidized low density lipoproteins downregulate LPS‐induced platelet‐activating factor receptor expression in human monocyte‐derived macrophages
Monocytes/macrophages play a key role in atherogenesis due to their inflammatory properties including formation of lipid mediators such as platelet‐activating‐factor (PAF). We investigated the effect of oxidized low‐density lipoprotein (oxLDL) on lipopolysaccharide (LPS)‐induced PAF receptor (PAF‐R) expression in human macrophages and the implication of the nuclear factor (NF)‐κB in this regulation. LPS‐treatment (1 µg·mL−1) of macrophages increased PAF binding and PAF‐R mRNA expression by 56% (P < 0.05) and twofold (P < 0.01), respectively. In contrast, highly oxidized low‐density lipoprotein [ox24hLDL; 100 µg·mL−1; thiobarbituric acid reacting substances: 31 ± 3 nmol equiv. malondialdehyde (MDA)·mg protein LDL−1] diminished PAF‐R expression (−69%; P < 0.05) and mRNA level (− 45%; P < 0.01). LPS pretreatment induced the activated form of p65 in the nuclear compartment of macrophages (detected by Western blotting) and NF‐κB binding activity (by electrophoretic mobility shift assay). Treatment of macrophages with ox24hLDL suppressed the LPS‐induced binding of NF‐κB to DNA. In addition, treatment of macrophages with lysophosphatidylcholine (2 and 10 µm), a major component of oxLDL, inhibited the LPS‐induced NF‐κB binding to DNA and reduced PAF binding by 30 and 70%, respectively. In conclusion, oxLDL may downregulate PAF‐R expression in human macrophages by inhibiting LPS‐induced NF‐κB binding to DNA.
- 15 August 2001
- Published by Wiley in European Journal of Biochemistry
- Vol. 268 (16) , 4489-4496
Open AccessOxidized low density lipoproteins downregulate LPS‐induced platelet‐activating factor receptor expression in human monocyte‐derived macrophages
Monocytes/macrophages play a key role in atherogenesis due to their inflammatory properties including formation of lipid mediators such as platelet‐activating‐factor (PAF). We investigated the effect of oxidized low‐density lipoprotein (oxLDL) on lipopolysaccharide (LPS)‐induced PAF receptor (PAF‐R) expression in human macrophages and the implication of the nuclear factor (NF)‐κB in this regulation. LPS‐treatment (1 µg·mL−1) of macrophages increased PAF binding and PAF‐R mRNA expression by 56% (P < 0.05) and twofold (P < 0.01), respectively. In contrast, highly oxidized low‐density lipoprotein [ox24hLDL; 100 µg·mL−1; thiobarbituric acid reacting substances: 31 ± 3 nmol equiv. malondialdehyde (MDA)·mg protein LDL−1] diminished PAF‐R expression (−69%; P < 0.05) and mRNA level (− 45%; P < 0.01). LPS pretreatment induced the activated form of p65 in the nuclear compartment of macrophages (detected by Western blotting) and NF‐κB binding activity (by electrophoretic mobility shift assay). Treatment of macrophages with ox24hLDL suppressed the LPS‐induced binding of NF‐κB to DNA. In addition, treatment of macrophages with lysophosphatidylcholine (2 and 10 µm), a major component of oxLDL, inhibited the LPS‐induced NF‐κB binding to DNA and reduced PAF binding by 30 and 70%, respectively. In conclusion, oxLDL may downregulate PAF‐R expression in human macrophages by inhibiting LPS‐induced NF‐κB binding to DNA.